GT Biopharma (NASDAQ:GTBP) Posts Earnings Results, Misses Expectations By $0.45 EPS

GT Biopharma (NASDAQ:GTBP) announced its earnings results on Thursday. The company reported ($0.83) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.38) by ($0.45), FiscalAI reports.

GT Biopharma Trading Up 26.1%

Shares of GTBP stock traded up $0.19 during mid-day trading on Friday, reaching $0.92. The stock had a trading volume of 12,937,039 shares, compared to its average volume of 528,092. The stock’s 50-day moving average price is $0.72 and its two-hundred day moving average price is $1.70. GT Biopharma has a 52-week low of $0.54 and a 52-week high of $4.10. The firm has a market capitalization of $3.28 million, a PE ratio of -0.23 and a beta of 1.38.

Wall Street Analyst Weigh In

Several brokerages have issued reports on GTBP. Wall Street Zen lowered GT Biopharma from a “hold” rating to a “sell” rating in a research note on Saturday, September 20th. Weiss Ratings reissued a “sell (e+)” rating on shares of GT Biopharma in a report on Wednesday, October 8th. One equities research analyst has rated the stock with a Strong Buy rating, one has given a Buy rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, GT Biopharma has an average rating of “Moderate Buy” and a consensus target price of $11.00.

GT Biopharma Company Profile

GT Biopharma, Inc, a clinical stage biopharmaceutical company, focuses on the development and commercialization of immuno-oncology products based on its proprietary Tri-specific Killer Engager (TriKE) fusion protein immune cell engager technology platform. It develops GTB-3550, a single-chain tri-specific recombinant fusion protein conjugate that is in Phase I clinical trial for the treatment of myelodysplastic syndromes, refractory/relapsed acute myeloid leukemia or advanced systemic mastocytosis, and CD33+ malignancies.